文献速递甲状腺疾病

射频消融治疗伴BRAF V600E突变的单灶甲状腺微小乳头状癌

Radiofrequency Ablation of Unifocal Papillary Thyroid Microcarcinoma With BRAF V600E Mutation.
PubMed 文献 · J Clin Endocrinol Metab · 2023-01-01

回顾性分析60例伴BRAF V600E突变的单灶甲状腺微小乳头状癌患者接受超声引导下射频消融,平均最大径5.8±1.7 mm;全部实现扩大消融,末次随访42个(70.0%)结节完全消失,无局部复发及颈部淋巴结转移,声音改变(1.7%)为唯一主要并发症。

要点

  • 60例BRAF V600E突变阳性单灶PTMC行超声引导下射频消融,全部实现扩大消融。
  • 末次随访42个结节(70.0%)完全消失,18个(30.0%)消融区呈裂隙样改变。
  • 未检出局部复发或颈部淋巴结转移,声音改变(1.7%)为唯一主要并发症。

核心结论

  • 射频消融治疗伴BRAF V600E突变的单灶甲状腺微小乳头状癌有效且安全,尤其适用于无法手术或拒绝手术且不愿继续主动监测的患者。

研究设计与样本

  • 回顾性分析2020年1月至2021年12月接受超声引导下射频消融的60例伴BRAF V600E突变阳性单灶甲状腺微小乳头状癌患者(60个结节)。
  • 平均最大肿瘤直径为5.8±1.7 mm(范围2.5-10.0 mm)。
  • 所有甲状腺微小乳头状癌均经细针穿刺或粗针活检病理确诊,BRAF V600E突变经实时荧光定量聚合酶链反应确认为阳性。

主要发现

  • 全部入组患者均实现扩大消融。
  • 射频消融后即刻消融区尺寸较治疗前肿瘤增大;1个月后消融区尺寸较射频消融后即刻缩小。
  • 末次随访时42个结节(70.0%)完全消失,18个结节(30.0%)的消融区呈裂隙样改变。
  • 未检出局部复发或颈部淋巴结转移。
  • 声音改变(1.7%)为唯一主要并发症。

关键数值与推荐

  • 射频消融后即刻行超声造影评估是否实现扩大消融。
  • 射频消融后1、3、6、12个月及此后每6个月行超声评估消融区变化、局部复发及颈部淋巴结转移。

临床怎么用

  • 作者认为射频消融治疗伴BRAF V600E突变的单灶甲状腺微小乳头状癌有效且安全,尤其适用于无法手术或拒绝手术且不愿继续主动监测的患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: To date there is no study on the feasibility of radiofrequency ablation (RFA) for papillary thyroid microcarcinomas (PTMCs) with BRAF V600E mutation. OBJECTIVE: This study was designed to evaluate the efficiency, safety, and prognosis of ultrasound (US)-guided percutaneous RFA for unifocal PTMCs with BRAF V600E mutation. MATERIALS AND METHODS: Sixty patients with 60 unifocal BRAF V600E mutation-positive PTMCs who received US-guided RFA between January 2020 and December 2021 were retrospectively analyzed. The mean maximum PTMC tumor diameter was 5.8 ± 1.7 mm (range, 2.5-10.0 mm). All PTMCs were pathologically confirmed by fine needle aspiration or core needle biopsy, and BRAF V600E mutation was confirmed to be positive by real-time fluorescent quantitative polymerase chain reaction. Contrast-enhanced ultrasound (CEUS) was performed immediately after RFA to evaluate whether PTMCs were extendedly ablated. Ultrasound was performed 1, 3, 6, and 12 months after RFA and every 6 months thereafter to evaluate the changes in the ablation zone, local recurrence, and cervical lymph node metastasis (LNM). The complications were recorded and evaluated. RESULTS: Extended ablation was achieved in all enrolled patients. The ablation zone sizes increased immediately after RFA compared with those of tumors before treatment. One month later, the ablation zone sizes were smaller than immediately after RFA. At the last follow-up assessment, 42 nodules (70.0%) completely disappeared and the ablation zones of 18 nodules (30.0%) showed fissure-like changes. No local recurrence or cervical LNM was detected. Voice change (1.7%) was the only major complication. CONCLUSION: RFA is effective and safe in treating unifocal PTMCs with BRAF V600E mutation, especially when surgery is not feasible or refused by patients who are unwilling to continue active surveillance.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Lin Y, Wu ZR, Shi YP, et al. Radiofrequency Ablation of Unifocal Papillary Thyroid Microcarcinoma With BRAF V600E Mutation. J Clin Endocrinol Metab. 2023. PMID: 37220176. doi:10.1210/clinem/dgad269

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。